(Q28196934)

Prostaglandins, Leukotrienes and Essential Fatty Acids

PubMed

published in

0 references

volume

69

0 references

issue

2-3

0 references

page(s)

145-55

0 references

cites work

Specific physiological roles of cytosolic phospholipase A(2) as defined by gene knockouts

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Respective roles of the 14 kDa and 85 kDa phospholipase A2 enzymes in human monocyte eicosanoid formation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The role of leukotrienes in inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The biotransformation in vitro of cysteinyl leukotrienes in blood of normal and asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Characterization of the human cysteinyl leukotriene CysLT1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Characterization of the human cysteinyl leukotriene 2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Asthma and bronchial hyperresponsiveness linked to the XY long arm pseudoautosomal region

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Inhalation challenge with sulfidopeptide leukotrienes in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Asthmatic airways have a disproportionate hyperresponsiveness to LTE4, as compared with normal airways, but not to LTC4, LTD4, methacholine, and histamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effects of inhaled leukotriene D4 and platelet-activating factor on airway reactivity in normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Pulmonary gas exchange and sputum cellular responses to inhaled leukotriene D(4) in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effect of inhaled leukotriene D4 on airway eosinophilia and airway hyperresponsiveness in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Leukotriene E4 and granulocytic infiltration into asthmatic airways

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The effect of leukotriene C4 on mucin release into the cat trachea in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction In vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Role of leukotriene D4 in allergen-induced increases in airway smooth muscle in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Urinary leukotriene E4 excretion in exercise-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Persistent wheezing in very young children is associated with lower respiratory inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Inflammation, leukotrienes and the pathogenesis of the late asthmatic response.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist Montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

A randomized controlled trial of intravenous montelukast in acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

What is the role of nerves in chronic asthma and symptoms?

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Effect of oral prednisone on airway inflammatory mediators in atopic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

Churg-Strauss Syndrome in Patients Receiving Montelukast as Treatment for Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021

The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2803%2900075-9

7 January 2021